BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31267775)

  • 1. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization.
    Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
    J Asthma; 2020 Oct; 57(10):1092-1102. PubMed ID: 31267775
    [No Abstract]   [Full Text] [Related]  

  • 2. The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization.
    Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2409-2421. PubMed ID: 31749614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
    Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
    J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
    [No Abstract]   [Full Text] [Related]  

  • 4. The prevalence and disease burden of severe eosinophilic asthma in Japan.
    Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
    J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
    Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma.
    Lugogo NL; Kreindler JL; Martin UJ; Cook B; Hirsch I; Trudo FJ
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):171-176. PubMed ID: 32334141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.
    Kerkhof M; Tran TN; Soriano JB; Golam S; Gibson D; Hillyer EV; Price DB
    Thorax; 2018 Feb; 73(2):116-124. PubMed ID: 28918400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of severe asthma exacerbations in Spain: multicentre observational study.
    Quirce S; Melero C; Huerta A; Uría E; Cuesta M
    J Asthma; 2021 Feb; 58(2):207-212. PubMed ID: 31621441
    [No Abstract]   [Full Text] [Related]  

  • 9. Burden of asthma with elevated blood eosinophil levels.
    Casciano J; Krishnan JA; Small MB; Buck PO; Gopalan G; Li C; Kemp R; Dotiwala Z
    BMC Pulm Med; 2016 Jul; 16(1):100. PubMed ID: 27412347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.
    Heaney LG; Perez de Llano L; Al-Ahmad M; Backer V; Busby J; Canonica GW; Christoff GC; Cosio BG; FitzGerald JM; Heffler E; Iwanaga T; Jackson DJ; Menzies-Gow AN; Papadopoulos NG; Papaioannou AI; Pfeffer PE; Popov TA; Porsbjerg CM; Rhee CK; Sadatsafavi M; Tohda Y; Wang E; Wechsler ME; Alacqua M; Altraja A; Bjermer L; Björnsdóttir US; Bourdin A; Brusselle GG; Buhl R; Costello RW; Hew M; Koh MS; Lehmann S; Lehtimäki L; Peters M; Taillé C; Taube C; Tran TN; Zangrilli J; Bulathsinhala L; Carter VA; Chaudhry I; Eleangovan N; Hosseini N; Kerkhof M; Murray RB; Price CA; Price DB
    Chest; 2021 Sep; 160(3):814-830. PubMed ID: 33887242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England.
    Gokhale M; Hattori T; Evitt L; Lenney W; Nordstrom B; Collins J; Schultze A; Van Dyke MK
    Immun Inflamm Dis; 2020 Jun; 8(2):236-245. PubMed ID: 32222038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma.
    Ilmarinen P; Tuomisto LE; Niemelä O; Kankaanranta H
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):165-174.e4. PubMed ID: 29894793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between blood eosinophil count with asthma hospital readmissions.
    Gonzalez-Barcala FJ; San-Jose ME; Nieto-Fontarigo JJ; Carreira JM; Calvo-Alvarez U; Cruz MJ; Facal D; Garcia-Sanz MT; Valdes-Cuadrado L; Salgado FJ
    Eur J Intern Med; 2018 Jul; 53():34-39. PubMed ID: 29514744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of short-term pausing of oral corticosteroids on blood eosinophil count in patients with severe asthma.
    Biener L; Milger K; Suhling H; Korn S; Pizarro C; Skowasch D
    Pneumologie; 2023 Jun; 77(6):357-362. PubMed ID: 36384226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
    Burnette A; Wang Y; Rane PB; Chung Y; Princic N; Park J; Llanos JP; Lindsley AW; Ambrose CS
    J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
    [No Abstract]   [Full Text] [Related]  

  • 19. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.
    Korn S; Cook B; Simpson LJ; Llanos JP; Ambrose CS
    Adv Ther; 2023 Jul; 40(7):2944-2964. PubMed ID: 37233876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.